Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF)

The QualityStocks Daily Newsletter would like to spotlight Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF).

Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF) (FSE: 7CR), a propriety SaaS technology company delivering mobile-first live-dealer technology to online gaming operators globally, has signed a software license and distribution agreement with Markor Technology, a global iGaming supplier. Markor Technology has built a reputation for offering products driven by data science and machine-learning automation. The company’s multivertical portfolio includes state-of-the-art iGaming platform (“PAM”), white-label solutions, game aggregation and managed services. According to the three-year agreement, Markor Technology will add Playgon's exclusive, mobile-first Vegas Lounge live dealer and e-table offerings to its content library, where it will be available to a global client base; license fees will be based on commercial revenue-sharing rates. Both companies noted that integration work had been completed with client testing and onboarding starting immediately. "We are delighted to team up with Markor Technology," said Playgon Games president and CEO Darcy Krogh in the press release. “I first met up with the Markor team in London at this year’s ICE conference in April and was impressed with their strategy and vision. They are an experienced team with significant client reach and have already secured a few key customer accounts through their network and look forward to many more in the future.” To view the full press release, visit https://ibn.fm/11UU3

Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) is a SaaS technology company focused on developing and licensing digital content for the growing global iGaming market. The company provides a multi-tenant gateway that allows online operators the ability to offer their customers innovative iGaming software solutions. Its current software platform includes Live Dealer Casino, E-Table Games and Daily Fantasy Sports. Seamless integration at the operator level allows customer access without requiring the sharing of any sensitive customer data. Playgon games run on any browser and any device as fast and secure as a native app, without requiring any app store download. All that’s needed is a stable internet connection. The gaming experience is identical across all mobile devices. As a true business-to-business digital content provider, the company’s products are scalable turnkey solutions for online casinos, sportsbook operators, location-based operators, media groups, and big database companies.

Playgon’s proprietary technology provides digital games for online gambling sites and mobile device apps, with the company licensing its mobile live-dealer technology to online gaming operators worldwide. Playgon combines high definition live streaming dealers with state-of-the-art augmented reality betting to provide the most authentic casino experience, live from Las Vegas. Playgon’s mobile platform features popular table games, all optimized for one-handed play on mobile devices.

The COVID-19 pandemic has accelerated an already existing shift away from location-based casinos to online gambling. At the same time, the proliferation of mobile devices has provided players with new access to betting. A younger, tech-savvy consumer demographic is driving adoption of digital gaming globally. To meet this demand, Playgon has launched a studio with 10 gaming tables from which its live dealer streaming video originates. The company’s platform is live with multiple online casino operators through four aggregator clients in South Africa and Europe, and commitments are coming in from more.

Playgon plans to expand the studio to 25 tables in the near term and is working to establish a U.S. strategy. The company will continue to expand licensing of its live dealer games to iGaming operators worldwide under a SaaS license agreement. As a B2B software supplier, Playgon avoids player acquisition costs.

Games

Live Dealer Casino

Playgon offers the first and only Live Dealer Casino streaming live from Las Vegas. The company brings cutting-edge handheld features and functionality to the mobile generation of gaming enthusiasts who demand a world-class gaming experience on all devices. Playgon’s Blackjack delivers the look and feel of location-based casino tables with features providing players with the most unique user experience. The company’s true-to-life Roulette offers players a clear and uninterrupted view of the dealer, wheel, ball, bets, results, trends and statistics. Players can strategize, place multiple bets, track results and review trends without ever losing focus of the game.

Playgon’s traditional Baccarat and proprietary Tiger Bonus Baccarat™ prove their worth by not only recognizing the need for a prominent product, but by adding elements which separate them from the pack without removing their authenticity. The games mix advances in technology with the traditional game attributes that have resonated and captivated players for hundreds of years.

eTable Games

To lead the rise of mobile-first gaming, Playgon developed a user experience perfected for one-handed play. Providing this next evolution in gaming technology ensures the company’s client operators loyalty from existing customers and is a powerful strategy to attract and retain new players. Playgon’s VEGAS LOUNGE™ brings together an innovative mix of games, technology and gameplay that offers players an authentic experience and real Las Vegas casino fun every time, everywhere.

Daily Fantasy Sports

Playgon’s Daily Fantasy Sports (DFS) are a subset of fantasy sport games which typically target a younger demographic. DFS provides iGaming operators a turnkey fantasy sports platform that can quickly go to market, integrate with the operator’s existing operations and services, and be customized to match and enhance the operator’s brand. The platform is mobile and desktop friendly, built for regulated market environments, and allows operators to monetize users through a network of shared liquidity.

Market Outlook

Online casinos and sports betting sites/apps are increasingly adding market share to traditional location-based casinos. This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, as well as tech like digital wallets and digital gameplay that underpins Playgon Games. The company has been described as “Netflix + Vegas, all in one.”

The online gambling market is slated to reach a value of $127.3 billion by 2027, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25 percent year over year. The current global online Live Casino TAM is estimated at about $6 billion annually, and revenue is forecast to reach more than $8 billion by 2023 and more than $13 billion by 2027.

Management Team

Darcy Krogh is CEO of Playgon Games. He is a veteran of the iGaming industry with over 20 years of experience. In 1999, he co-founded Chartwell Technology Inc., which pioneered the development of browser-based digital content for the iGaming industry. After that company was sold to Amaya Gaming Group, he served as VP Business Development with Amaya. In 2016, he started Playgon Games (formally Global Daily Fantasy Sports Inc.) as President and CEO. His experience in the online gaming industry includes sales and marketing, relationship management, corporate finance, M&A, and strategic corporate development.

Guido Ganschow is President of Playgon Interactive. He has more than 12 years of experience in creating real-time Live Dealer technology and platforms and was the co-founder and Creative Director for a Macau-based casino consortium. Between 2008 and 2014, he successfully created and established Live Dealer platform businesses in Asia and Europe, and executed commercial partnerships, sales, and integration of the Live Dealer solution with major global gaming brands, including Ho Gaming Group, Chartwell Technology and Amaya Gaming Group.

Steve Baker is COO of Playgon. He is a former VP Operations for Shaw Communications, where he was directly involved in video streaming, home entertainment, new products, sales and M&A. He oversaw revenue growth from $300 million to $2.8 billion and employee growth from 350 to 13,000. He has broad experience and a proven record in development and implementation of cost effective and efficient growth strategies transitioning businesses from development to operations.

Harry Nijjar is CFO of Playgon Games. He is currently a Managing Director with Malaspina Consultants Inc. and provides CFO and strategic financial advisory services to his clients across many industries. This experience has allowed him to help his clients successfully navigate the regulatory and financial environments within which they operate. Mr. Nijjar holds a CPA-CMA designation from the Chartered Professional Accountants of British Columbia.

Playgon Games Inc. (PLGNF), closed Thursday's trading session at $0.06196, up 21.0156%, on 2,010 volume. The average volume for the last 3 months is 2,010 and the stock's 52-week low/high is $0.0416/$0.406.

Recent News

• Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) - InvestorNewsBreaks - Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) (FSE: 7CR) Inks Licensing, Distribution Deal with Global iGaming Supplier
• InvestorNewsBreaks - Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) (FSE: 7CR) Releases Q1 2022 Financial Report
• InvestorNewsBreaks - Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) (FSE: 7CR) Applies for Gaming Related Supplier Approval for Ontario, Canada

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced its launch of B2B sales of the rare cannabinoid delta 9-dominant tetrahydrocannabivarin (“d9-THCV”) into the health and wellness sector via its wholly owned subsidiary, BayMedica LLC. “We are very excited to launch our highly anticipated d9-THCV and further enhance BayMedica’s growing product portfolio,” said Shane Johnson, MD, SVP and general manager of BayMedica. “THCV is one of the few rare cannabinoids that has been researched in early clinical trials for various therapeutic effects, fueling significant interest by end-product manufacturers and consumers alike. In anticipation of this launch, we have expanded internal sales and marketing infrastructure, developed new distribution channels and optimized the supply chain to ensure a consistent and reliable supply of a high quality product. As this market continues to mature, we are well positioned to be a leading supplier of rare cannabinoids to the health and wellness industry. We currently have several high-value, rare cannabinoids in various stages of commercial development and will continue to expand our cannabinoid portfolio over the coming years.” To view the full press release, visit https://ibn.fm/32GqZ

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Thursday's trading session at $0.66, up 0.747977%, on 378,850 volume. The average volume for the last 3 months is 378,404 and the stock's 52-week low/high is $0.625/$3.51.

Recent News

• InMed Pharmaceuticals Inc. (NASDAQ: INM) - InvestorNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Portfolio of Rare Cannabinoids with Launch of d9-THCV
• InvestorNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $5M Direct, Private Placement Offerings
• InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF).

EverGen (TSX.V: EVGN) (OTCQB: EVGIF), Canada’s renewable natural gas (“RNG”) infrastructure platform, today announced that the TSX Venture Exchange (“TSXV”) has approved the company’s Normal Course Issuer Bid (“NCIB”). The NCIB will allow EverGen to purchase issued and outstanding common shares of EverGen through the facilities of the TSXV during a 12 month period, commencing on June 8, 2022, and ending on June 7, 2023, or such earlier date as EverGen may complete its purchases pursuant to the NCIB or as it may otherwise determine. According to the update, the company implemented the NCIB because it believes that, from time to time, the market price of the common shares may not fully reflect the underlying value of EverGen’s business and its future prospects. Accordingly, the company believes that having the ability to purchase the common shares using cash flow will be in the interest of the company and represents an opportunity to enhance shareholder value. No previous purchases of common shares have been completed by EverGen pursuant to an NCIB. To view the full press release, visit https://ibn.fm/Qdvs0

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQB: EVGIF), closed Thursday's trading session at $2.81, even for the day. The average volume for the last 3 months is 500 and the stock's 52-week low/high is $2.12/$4.21.

Recent News

• EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) - InvestorNewsBreaks - EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) Announces Approval of NCIB by TSX Venture Exchange
• EverGen Infrastructure Corp. Announces Approval of Normal Course Issuer Bid by the TSX Venture Exchange
• EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) Poised to Execute Rapid Growth Strategy; Announces Acquisition of 50% Stake in Project Radius in Ontario

Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

• Correlate Infrastructure Partners is a company that develops and finances renewable energy projects for the commercial real estate industry
• Its services address heating, cooling, and lighting solutions with clean onsite generation that allows CIPI and its clients to reach for Net Zero goals while supporting new electric vehicle infrastructure growth
• The improvement of charging stations is linked to greater adoption of EVs and, with it, the capacity of electricity generated from renewable sources will have to increase to meet the demand
• CIPI is playing a preparatory role by increasing renewable generation capacity at its clients’ facilities and installing EV charging infrastructure

Countries, businesses, and people are racing against time to reduce their carbon footprint and emissions in line with the Paris Agreement. With the transportation sector, which is predominantly reliant on fossil fuels, accounting for roughly 27% of total U.S. greenhouse gas (“GHG”) emissions (https://ibn.fm/f2kOZ) and about 25% of global GHG emissions (https://ibn.fm/9bW3e), electrification of transport has emerged as a central pillar if the Agreement’s goals are to be realized. As a result, EV sales are surging.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.

Subsidiaries

Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Thursday's trading session at $1.19, even for the day. The average volume for the last 3 months is 3,300 and the stock's 52-week low/high is $0.30/$3.25.

Recent News

• Correlate Infrastructure Partners Inc. (OTCQB: CIPI) - Correlate Infrastructure Partners Inc. (CIPI) Committed to Putting Clean Energy in Every Business, Home, Electric Vehicle
• Correlate Infrastructure Partners Inc. (CIPI) Applies for Uplisting to the NASDAQ Exchange, Aims at Achieving Increased Investor Awareness
• Correlate Infrastructure Partners Inc. (CIPI) Builds on Data Transparency Platform to Improve ESG Reporting in Renewable Energy Solutions Market

Prime Harvest Inc.

The QualityStocks Daily Newsletter would like to spotlight Prime Harvest Inc.

Jaxx Cannabis is carving out a top spot in the cannabis world with its renowned customer service and quality products. The flagship brand in a portfolio of superior offerings from Prime Harvest, Jaxx features an expertly curated selection of premium products from some of the most respected brands in the thriving California market. Jaxx products are carefully selected to combine valued and quality to create an experience focused and centered on consumers. Jaxx Cannabis has differentiated itself in the cannabis space by creating and nurturing a welcoming culture for everyone and being innovative in uncovering new ways to grow both the company and the industry. Jaxx understands the strong connection between meeting the needs and wants of consumers with profitability, and the company is accountable to do both. 

Prime Harvest Inc., based in San Diego, California, is a technology-focused, full-service cannabis company with horizontally diversified operations spanning various segments of the cannabis value chain, from licensing acquisition and compliance management to direct-to-consumer operations. The company is leveraging a long-term strategy of investing in the growth and scale of licensed assets anchored by the power of data-driven technology to expand its footprint throughout California.

Sustainability is key to Prime Harvest’s corporate vision. The company aims to ensure that the communities it serves capture their fair share of the fruits of the industry’s growth, including financial profit, employment opportunities, environmental enrichment and impactful innovation through R&D and education.

The company’s mission is to appeal to the ethos of the cannabis consumer by setting a new operational standard emphasizing accountability, sustainability and community. With this commitment, Prime Harvest continues to work toward positively affecting millions of lives through the creation of a world-class platform that caters to strengthening the commercial cannabis pipeline.

Jaxx Cannabis

Jaxx Cannabis is the flagship brand in Prime Harvest’s portfolio. Through Jaxx Cannabis, the company aims to use technology to facilitate a true customer-centric culture while enhancing the overall craft cannabis experience. Jaxx features an expertly curated selection of premium products from some of the most respected brands in the thriving California market.

Key values serving as the foundation of Jaxx Cannabis include:

• Creating and nurturing a welcoming culture for all
• Unlocking the true potential of customer value
• Being innovative in uncovering new ways to grow both the company and the industry
• Meeting the wants and needs of consumers to promote profitability
• Remaining accountable for the results of its operations

It is these values that differentiate Prime Harvest and Jaxx Cannabis in the California cannabis sector.

Brand Partnerships

Prime Harvest works diligently to establish strong alliances with complementary brands that are in alignment with its culture and values. Through a combination of deliberate foresight and strategic action, the company seeks to grow existing cannabis brands and continuously discover new, high-potential performers that are primed for long-term success.

These partnerships enhance Prime Harvest’s efforts to transform the world’s cannabis access and bring its consumers high-quality products that are fair for both people and the planet.

Responsibility

Prime Harvest remains committed to the goal of creating a more sustainable environment, now and in the future. Concern for human beings and the environment can be observed in every facet of its operations, including its ongoing R&D activities dedicated to exploring methods of reducing and repurposing waste into composite materials and exploring the potential of the hemp plant for industrial and wellness contributions.

The company is a proud member of the Community Alliance Program, a foundation that seeks to make a difference in local communities by providing financial assistance for educational programs, housing homeless veterans, creating urban farms, and holding local arts initiatives for children and adults. The program also helps explore the natural healing attributes of medical cannabis through research, development, clinical trials, and advocating for the safe access of cannabis to those in need.

Market Overview

Ongoing changes in U.S. state government policies toward cannabis are expected to cause demand for legal marijuana to surge. In addition, the number of indications for which medical marijuana is prescribed continues to increase. These factors are expected to rapidly boost legal sales of cannabis products.

Legal sales across the U.S. hit a record of $17.5 billion in 2020, marking an increase of 46% over 2019, according to Forbes. This strong growth is expected to continue. According to a Grand View Research report, the global legal marijuana market is forecast to grow at a CAGR of 26.7 percent from 2021 to 2028.

California – Prime Harvest’s home state – has consistently led the pack in terms of U.S. cannabis sales. The Motley Fool pegged cannabis spending in the Golden State at $3.8 billion in 2020, more than doubling the second state on its list.

Leadership Team

The Prime Harvest team is composed of true experts in their respective fields focused on building a world-class organization capable of driving the cannabis industry and movement forward.

E. Duane Alexander is the company’s Founder and CEO. He brings to the team more than 25 years of real-world, hands-on cannabis retail, marketing and commercial operations experience. Mr. Alexander has championed 40+ cannabis license applications throughout the western U.S. to date.

John Wilczak is the COO of Prime Harvest. He has 30+ years of executive management, strategy development & configuration experience with GE, pharmaceutical and agriculture companies. Mr. Wilczak is a Brown & Columbia MBA with vast knowledge of technology driven intellectual properties.

Andrea Jenson is the Chief Financial Officer of Prime Harvest. As CFO, she is responsible for all the company’s financial functions, including accounting, corporate finance and investor relations. Her career spans more than 20 years of varied experience in financial management, business leadership and financial strategy.

John Kazanjian is the VP of Business Development of Prime Harvest. He has worked over 40 years in business operations, brand marketing, sales and investor/lender communications. Mr. Kazanjian earned his B.S. from Rutgers University and his MBA from Harvard University.

Johann Balbuena is the Chief Marketing Officer of Prime Harvest. She has more than six years of experience in California cannabis licensing acquisition and compliance management. Ms. Balbuena has led multimedia production and content marketing efforts for the likes of the Social Club TV app, The Emerald Cup, High Times, Weedmaps and Synergy.

Recent News

• Prime Harvest Inc. - With a Focus on Accountability, Prime Harvest Inc. Continues to Grow as a Leader in California’s Cannabis Industry
• InvestorNewsBreaks – Prime Harvest Inc. Selects IBN for Corporate Communications Expertise
• InvestorNewsBreaks – Why Prime Harvest Inc. Is ‘One to Watch’

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

It would seem that the age of the internal combustion engine is beginning to draw to a close. After being the main form of vehicle transportation for more than a century, ICE vehicles are poised to be replaced by zero-emission electric cars. According to a new report from Bloomberg New Energy Finance, sales of gas- and diesel-powered vehicles have taken a permanent nose dive as more people opt for plug-in hybrids and battery-electric cars. The report states that plug-in hybrid sales are expected to triple by 2024. Consumers will buy 20.6 million plug-in electric cars in 2025 compared to 6.6 million in 2022. Furthermore, industry analysts and lead authors of the report Aleksandra O’Donovan and Colin McKerraracher say the market is beginning to rely on organic consumer demand rather than government policy to grow. Either way, the Bloomberg analysts say, there is little chance of ridding road transport of carbon by 2050, even if transportation is 100% emission free. The public needs more solutions if we are to solve the climate crisis before it’s too late, and manufacturers such as Mullen Automotive Inc. (NASDAQ: MULN) can play their part by availing the variety of EVs that the public would buy to reduce the carbon burden upon the planet.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Thursday's trading session at $1.2, off by 6.25%, on 41,913,664 volume. The average volume for the last 3 months is 41.162M and the stock's 52-week low/high is $0.52/$15.90.

Recent News

• Mullen Automotive Inc. (NASDAQ: MULN) - Report Says ICE Vehicle Sales Have Gone into Permanent Decline
• InvestorNewsBreaks - Mullen Automotive Inc. (NASDAQ: MULN) Announced Addition to Russell 2000(R), 3000(R) Indexes
• Old ICE Vehicles Could Soon Be Used to Make Electric Vehicles

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Cannabis may be colloquially known as weed, but the truth is that cultivating a batch of healthy and profitable cannabis plants requires plenty of care and attention to detail. A fickle plant in many ways, cannabis often gives cultivators a hard time, especially if those cultivators are commercial growers with large scale cultivations. One major issue that plagues commercial growers and has the potential to reduce their yield is pollination. Cannabis is dioecious, which means it produces male and female flowers on separate plants. Once female plants are pollinated, the quantity and quality of their yield is reduced significantly. As such, the cannabis industry has come to revere seedless varieties that do not produce seeds. A special strain dubbed cannabis sinsemilla, which is Spanish for “without seeds,” was created in the 1970s by separating female plants from their pollen-producing male counterparts. It could be interesting to see how those seedless cannabis varieties would perform when grown in the high-tech micro gardens made by Advanced Container Technologies Inc. (OTC: ACTX) and other such companies.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Thursday's trading session at $0.75, off by 9.3656%, on 5,895 volume. The average volume for the last 3 months is 5,895 and the stock's 52-week low/high is $0.54/$3.575.

Recent News

• Advanced Container Technologies Inc. (OTC: ACTX) - 420 with CNW - Seedless Strains Could Dominate Future of Marijuana Industry
• 420 with CNW - Regulators in New York Urge Tiktok to Desist from Banning Educative Cannabis Content
• 420 with CNW - Cannabis MSOs Hire Prominent Law Firm to Sue Federal Government

Aditxt Inc. (NASDAQ: ADTX)

The QualityStocks Daily Newsletter would like to spotlight Aditxt Inc. (NASDAQ: ADTX).

Aditxt (NASDAQ: ADTX), a biotech innovation company, today announced that it has selected the corporate communications expertise of IBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company for private and public entities. As part of the relationship, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs, and other outreach tools to generate greater awareness for Aditxt. “The potential market opportunities presented by immune monitoring and reprogramming are extensive. Through its work in the COVID-19 testing market with AditxtScore(TM), Aditxt demonstrated this potential. The company is now uniquely positioned to leverage its existing infrastructure as it works to evaluate broader applications for AditxtScore(TM),” said Chris Johnson, director of client solutions for IBN. “We’re excited to customize our comprehensive suite of corporate communications solutions for Aditxt as it continues to advance its development pipeline while scaling capabilities at its immune monitoring center in Richmond, Virginia.” To view the full press release, visit https://ibn.fm/ErDUi. New research has found that individuals with some food allergies may have a reduced risk of contracting the coronavirus. The Human Epidemiology and Response to SARS-CoV-2 (HEROS) study was sponsored and funded by the National Institutes of Health. Its findings were published in the “Journal of Allergy and Clinical Immunology.” The objective of the study was to determine if allergic illnesses such as asthma were linked to household transmission of the SARS-CoV-2 infection. For their research, the scientists following coronavirus infections in more than 4,000 individuals in about 1,400 households in which at least one individual aged 21 or below lived. The scientists monitored the individuals between May 2021 and February 2021 across 12 cities in America before vaccines were rolled out to the public. While these food allergies may have surprised researchers by showing their beneficial side, by their very nature, allergies compromise the health and well-being of patients. That is why companies such as Aditxt Inc. (NASDAQ: ADTX) focus on develop novel treatments aimed at reprogramming the immune system so that allergies are brought under control or even eliminated.

Aditxt Inc. (NASDAQ: ADTX) is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

As further discussed below, the company’s first commercial product is an immune mapping technology, AditxtScore™, which is designed to provide a personalized profile of the immune system.

The company’s preclinical immune reprogramming technology, Apoptotic DNA Immunotherapy™ (“ADi™”), aims to retrain the immune system to induce tolerance, with the goal of addressing vast unmet needs in transplanted organ rejection, autoimmune diseases, and allergies. The company is developing specific ADi™ products for psoriasis, type 1 diabetes, and skin grafting.

Headquartered in Richmond, Virginia, Aditxt also operates locations in Silicon Valley and New York.

AditxtScore™

AditxtScore™ is a proprietary platform designed to provide a personalized, comprehensive profile of an individual’s immune system. The underlying technology, licensed from Stanford University through an exclusive worldwide agreement, offers a highly sensitive and accurate method of detecting and quantifying cellular responses, allowing greater specificity, quantification, and amplification of both clinical and commercial opportunities.

The company’s first commercial application of the platform, AditxtScore™ for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 and its known variants, giving consumers and physicians the data needed to make informed health decisions. Potential future applications will offer early detection of an array of conditions, including diabetes, cardio-metabolic maladies and hormonal imbalances.

Aditxt’s AditxtScore™ immune monitoring center in Richmond, Virginia, is operational and designed to support the anticipated increased demand for AditxtScore™ as well as related products and services. The company is currently scaling its capabilities at this location, with a goal of processing up to 10 million immune system tests/reports annually.

ADi™

ADi™ is Aditxt’s immune reprogramming platform addressing disease-causing immune responses while maintaining the immune system’s ability to combat pathogenic infection. The company is commercializing a nucleic acid-based technology called Apoptotic DNA Immunotherapy™ (ADi™) which utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues (therapeutically induced immune tolerance). Aditxt believes its ADi™ technology platform can be engineered to address a wide variety of indications.

Aditxt is currently developing ADi™ products for psoriasis, type 1 diabetes and skin grafting.

Currently, immuno-tolerance is achievable through chimerism and cell-based therapy, but there is a clinical need for a more practical and cost-effective approach which:

• Can be made into a product
• Does not require additional hospitalization
• Is simple to produce and ship

Preclinical studies have demonstrated that ADi™ treatment significantly and substantially prolongs graft survival, in addition to successfully “reversing” other established immune-mediated inflammatory processes. ADi™ treatment is not expected to require hospitalization, instead being delivered as an injection in minute amounts into the skin.

IP Portfolio

Both AditxtScore™ and ADi™ are supported by a strong IP portfolio.

AditxtScore™, built upon initial technology invented, licensed from and used at Stanford University, is protected by U.S. patents encompassing methods, systems, and kits for detection and measurement of specific immune responses.

ADi™ technology is protected by seven patent families, including:

• 8 U.S. patents
• 4 pending U.S. patent applications
• 86 foreign patents and 14 pending foreign patent applications spanning the EU, Australia, Canada, Japan, China, India and Hong Kong

These patents are broadly categorized into three groups:

• Autoimmune diseases and Type 1 Diabetes
• Organ transplantation and a method of producing plasmid DNA to prevent immune activation
• Composition of matter for a tolerance delivery system for antigens of interest

Aditxt also possesses and/or in-licenses substantial know-how and trade secrets relating to the development and commercialization of its product candidates, including related manufacturing processes and technologies.

Market Overview

The potential market opportunities presented by immune monitoring and reprogramming are extensive, particularly as Aditxt continues to evaluate additional applications for the platforms.

The company’s initial focus on organ transplantation and related autoimmune response provides some insight into the potential of its approach. According to BCC Research, the global organ and tissue transplantation and alternatives market is on course to reach $120.3 billion by 2024, recording a CAGR of 7.4% from 2019. Industry data suggest that approximately 50% of all transplanted organs are rejected within 10-12 years, further highlighting the critical need for a practical, cost-effective solution to harmful autoimmune responses.

Through its focus on the COVID-19 testing market with AditxtScore™, Aditxt demonstrated the wide-ranging potential of its portfolio. Fortune Business Insights estimated the global COVID-19 diagnostics market at $48.64 billion for 2022. While demand for COVID-19 diagnostics is expected to lessen in the coming years, Aditxt will be uniquely positioned to leverage its existing infrastructure stemming from these operations as the company works to advance broader applications for the AditxtScore™ platform.

Leadership Team

Amro Albanna is the Co-Founder, Chairman, and CEO of Aditxt. He has founded multiple startups to commercialize innovations in various industries, including healthcare, enterprise software, telecommunications, nano technology, consumer health, and biotech. Mr. Albanna has led numerous M&A and going-public transactions as a founder, co-founder, and senior executive.

Shahrokh Shabahang, D.D.S., MS, Ph.D., is the company’s Co-Founder, Chief Innovation Officer, and a member of its board. He brings to the team more than 20 years of experience in developing and commercializing life science technologies focused on product and clinical development in the fields of microbiology and immunology.

Corinne Pankovcin, CPA, MBA, is the President of Aditxt. Prior to joining Aditxt, Ms. Pankovcin served as CFO for several world class organizations, including Business Development Corporation of America, Blackrock Kelso Capital and AIG Capital Partners. In these roles, Ms. Pankovcin was responsible for executing portfolio investments and managing significant M&A transactions.

Thomas Farley is the Chief Financial Officer of Aditxt. From December 2015 to June 2020, Mr. Farley was the Controller and Treasurer of Business Development Corporation of America (“BDCA”), a publicly listed business development company. Prior thereto, from January 2011 to August 2015, Mr. Farley was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ: BKCC). Prior to joining BlackRock Capital Investment Corporation, Mr. Farley was a Senior Controller for PineBridge Investments Emerging Markets practice. Mr. Farley was also an Accounting Manager for Bessemer Venture Partners prior to his tenue at PineBridge. Mr. Farley began his career with PricewaterhouseCoopers LLP, from 1996 to 2001. Mr. Farley earned his B.S. in Accounting from Long Island University and is a Certified Public Accountant.

Rowena Albanna is the company’s Chief Operating Officer. Ms. Albanna has over two decades of experience in senior leadership roles for both technology startups and public companies. Ms. Albanna’s experience spans a wide variety of industries, including biotechnology, insect control, nanotechnology, consumer electronics, financials, telecommunications, e-commerce, online marketing, medical, and defense.

Matthew Shatzkes is the Chief Legal Officer and General Counsel of Aditxt. As a former partner at an AM Law 50 law firm, Mr. Shatzkes advised a wide variety of healthcare related entities, including biotech companies, on corporate, regulatory, and strategic business matters. Mr. Shatzkes will oversee all aspects of the legal functions at Aditxt, including, providing advice and counsel on governance, regulatory matters, strategic alliances, mergers and acquisitions, and commercial transactions.

Aditxt Inc. (NASDAQ: ADTX), closed Thursday's trading session at $0.2979, off by 0.7%, on 1,440,128 volume. The average volume for the last 3 months is 1.429M and the stock's 52-week low/high is $0.2412/$3.95.

Recent News

• Aditxt Inc. (NASDAQ: ADTX) - Study Says Some Allergies Lower Covid Infection Risk
• InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Engages IBN for Corporate Communications Expertise
• BioMedNewsBreaks - Aditxt Inc.'s (NASDAQ: ADTX) Immune Monitoring Platform 'Is the Right Technology at the Right Time'

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

A new study that looked into the relationship between an individual’s response to fear and the use of MDMA has found that combining this drug with recall therapy and fear extinction learning substantially decreased the fear felt by individuals involved in the study. This comes after MAPS recently released promising results from its phase III clinical trial, which found that MDMA-assisted therapy could be beneficial to patients with PTSD. The MindMed-linked research was carried out by scientists based at the University Hospital of Basel, which is located in Switzerland. Their objective was to test whether the use of MDMA could improve the fear-extinction learning and recall therapy. Despite the conflicting results, one thing is clear: individuals with PTSD may gain relief from MDMA-assisted therapy, and companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) are investing every effort possible to bring these needed psychedelic treatments to market.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Thursday's trading session at $0.6312, off by 8.5217%, on 857,143 volume. The average volume for the last 3 months is 754,170 and the stock's 52-week low/high is $0.3903/$3.38.

Recent News

• Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) - New Study Suggests That MDMA May Decrease Fear, Boost PTSD Treatment
• New Research Finds That Individuals Prefer Guide with Personal Psilocybin Experience
• InvestorNewsBreaks - Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Acquisition of Entheon Biomedical's DMT Clinical Study

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, is featured in the latest interview released by the RedChip Money Report and aired on Bloomberg TV. The interview with Odyssey Health CEO Michael Redmond is slated for broadcast at 7 p.m. ET on June 11. During the interview, which is hosted by RedChip CEO Dave Gentry, Redmond discusses the company, including the development of its novel compound, which could be the first FDA-approved treatment for concussions. With more than 5 million concussions reported in the United States each year and an estimated 69 million occurring worldwide, the potential in the $400 billion market is significant. In addition, Redmond provides an overview of ODYY’s medical products pipeline, including CardioMap(R), a monitoring and screening device for early detection of coronary artery disease, and Save-A-Life(R), a handheld choking rescue device for consumer use. The RedChip Money Report is produced by RedChip Companies Inc., an international investor relations and media firm with some three decades of experience. The RedChip Money Report delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. To view the full interview, visit https://ibn.fm/OHz5T. To view the full press release, visit https://ibn.fm/aTWSD.

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio

Pharmaceuticals

Odyssey has two pharmaceutical products in development:

• PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
  • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
• PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
  • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

• CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
  • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
• Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
  • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Thursday's trading session at $0.245, off by 0.588355%, on 7,684 volume. The average volume for the last 3 months is 7,684 and the stock's 52-week low/high is $0.11/$0.7998.

Recent News

• Odyssey Group International Inc. (OTC: ODYY) - InvestorNewsBreaks - Odyssey Health Inc. (ODYY) CEO Spotlighted in RedChip Money Report Interview
• BioMedNewsBreaks - Why Odyssey Health Inc. (ODYY) Is 'One to Watch'
• InvestorNewsBreaks - Odyssey Health Inc. (ODYY) Announces Positive Safety Findings from Clinical Trial of Concussion Drug

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF)

The QualityStocks Daily Newsletter would like to spotlight LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF).

LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a company focused on developing institution-grade payment infrastructure, liquidity and solutions for the Lightning Network (“LN”), is among companies that are not in the “watch and wait” mode when it comes to Bitcoin or the LN. This is despite observers’ expectations that the crypto market will stay in a bear phase for some time. “LQwD is still leveraging the Lightning Network with its platform as a service (‘PaaS’). LQwD launched its PaaS offering lqwd.tech in November 2021, the same time it launched its first node on the Lightning Network in the United States. Since then, LQwD has strategically launched many additional nodes worldwide,” a recent article reads. “The Bitcoin blockchain does not have the capacity to facilitate thousands of payments at one time, making the scaling of the Lightning Network even more important as acceptance of cryptocurrency rises. The Bitcoin Lightning Network continues to grow, despite the volatility of the actual market. As of recent reports (March 2022), the capacity of the Lightning Network currently exceeds 3,539 BTC.” To view the full article, visit https://ccw.fm/WYPnS

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) is a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption.

LQwD FinTech’s mission is to develop institutional-grade services that support the Lightning Network and drive improved functionality, transaction capability, user adoption and utility, and scaling of bitcoin. LQwD is also securing a substantial position in bitcoin as an operating asset and will use its holdings to establish nodes and payment channels on the Lightning Network.

The Lightning Network is a second-layer protocol, sitting above the bitcoin blockchain, intended to facilitate faster micro-transactions and lower fees on bitcoin transactions, thus allowing mass adoption of bitcoin.

LQwD expects the Lightning Network to eclipse the patchwork of legacy financial networks that are used to move value today. The company’s software will make migration from legacy networks onto the Lightning Network easy and seamless. By onboarding more financial service providers, LQwD intends to grow the value of the Lightning Network.

The company, formerly known as Interlapse Technologies Corp., is harnessing new payment rails built on top of the bitcoin blockchain that are capable of beyond visa-level transaction volumes and backed by bitcoin, the strongest and most well-known cryptocurrency. These new rails, enabled by the Bitcoin Lightning Network, open a vast opportunity and market segment for digital payments and financial services on a global scale. LQwD aims to leverage its position as a public company to enhance trust in its products and services, and leverage its shares as currency for acquisitions, roll-up and growth, as well as to attract and retain top industry talent.

Product

The Lightning Network is a solution to massively scale the use of bitcoin for microtransactions globally, dramatically improving upon fees, as well as providing instant settlement times. The Lightning Network has experienced explosive growth and is expected to continue with the trend as usage increases. Well-known companies, such as Twitter and Square, have expressed their enthusiasm to incorporate Lightning Network into their platforms. The Lightning Network is scalable, global, open, inclusive, permissionless and decentralized. It is made up of nodes connected via payment channels, and enables off-chain, instantaneous and cheap payments at scale.

Upon launch of LQwD’s Lightning Network platform-as-a-service, users will be able to leverage the Lightning Network infrastructure to send payments instantly, securely and inexpensively anywhere in the world. Companies and service providers will be able to conduct Lightning Network transactions in bitcoin by integrating LQwD’s infrastructure with their business or web property. Connected businesses will be able to easily deploy, monitor and manage LQwD’s Lightning Network nodes with no or low-level technical knowledge required. The company fully expects Lightning Network to be a force for global change and to become the monetary exchange network of the future.

The Lightning Network, which is already built, functioning and growing, will advance bitcoin from a store-of-value to a global monetary network through payment utility. The company expects the Lightning Network will propel the growing number of active blockchain wallets to new heights, by increasing bitcoin’s scalability and lowering its fees for users. For coming generations, everything from wealth to experiences will be acquired and transacted virtually, and LQwD sees the Lightning Network as an enabling technology that can bring bitcoin to hundreds of millions of new users across the globe.

Market Outlook

Forbes in August 2021 noted that “private investors are funding companies that are building the infrastructure that will support future growth of crypto and digital assets,” and called public companies building cryptocurrency infrastructure “the hottest part of the crypto market.” While the first wave of investor interest in crypto firms was directed at companies catering to retail investors, investors have now shifted their attention to infrastructure builders, like LQwD FinTech. Forbes did not put an estimated value on the crypto infrastructure market but pointed out that large-scale adoption of cryptocurrencies will only happen when infrastructure is in place to support it. The larger digital payments market, of which crypto payments are a small fraction, is growing at more than 14 percent annually and is forecast to hit $154 billion by 2025.

Management Team

Shone Anstey is co-founder, chairman and CEO at LQwD FinTech. He has 20 years of experience in building complex technologies and has acted as technology lead for an industrial bitcoin mine and bitcoin mining pool. He is a Certified Cryptocurrency Investigator, and an advisor to the British Columbia Securities Commission. He is also co-founder of BIGG Digital Assets (OTCQX: BBKCF) and took that company public in 2017.

Barry MacNeil is CFO at LQwD FinTech. He is a member of the Chartered Professional Accountants of British Columbia and has more than 30 years of management and accounting experience with public companies and in private practice. His previous positions include director of both public companies and nonprofits, as well as Chief Financial Officer and Corporate Controller.

Albert Szmigielski is co-founder and CTO at LQwD FinTech. He was formerly the Head of Research and Chief Blockchain Engineer at Blockchain Intelligence Group and VP Research at CipherTrace. He holds a B.Sc. in Computing Science from Simon Fraser University, and a Master of Science in Digital Currencies and Blockchain Technologies from the University of Nicosia, Cyprus.

LQwD FinTech Corp. (LQWDF), closed Thursday's trading session at $0.143, off by 5.9211%, on 20,790 volume. The average volume for the last 3 months is 20,790 and the stock's 52-week low/high is $0.0754/$0.8102.

Recent News

• LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) - LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Adds New Member to Board; Releases New Lightning Network Node in South Korea
• CryptoNewsBreaks - LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Scaling Lightning Network, Making Bitcoin Transactions Possible
• InvestorNewsBreaks - LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Appoints New Director

Kronos Advanced Technologies Inc. (OTC: KNOS)

The QualityStocks Daily Newsletter would like to spotlight Kronos Advanced Technologies Inc. (OTC: KNOS).

Kronos Advanced Technologies (OTC: KNOS) recently completed the acquisition of an 85,000-square-foot West Virginia manufacturing campus that will be retrofitted to produce advanced, proprietary air-purification devices and other wellness products. With this move, Kronos is committed to manufacturing completely on American soil. “Nearly two years ago, we set into motion a strategic plan to transform Kronos from a marketing and fulfillment company, positioned within the fragmented market space of air purification, into a globally dominant consumer product design and manufacturing company… This acquisition is a key foundational milestone in our transformation,” a recent article quotes Kronos COO and CTO Joseph Florence as saying. “Kronos is confident that this acquisition will enable us to focus on the efficient fulfillment of our current product line, the utilization of our recently acquired equipment to begin offering contract manufacturing services, and the ability to initiate the transition of our conceptual designs into production.” To view the full article, visit https://ibn.fm/KHlxv

Kronos Advanced Technologies Inc. (OTC: KNOS) develops and sells a variety of disruptive, advanced, state-of-the-art air filtration and purification systems that fully remove harmful allergens, bacteria, viruses (including the flu), and even gasses from indoor breathing spaces, including healthcare and other settings.

Kronos’ own patented medical-grade technology is tested as the most effective clean air solution on the market. Kronos filters particles down to .0146 micron (.0146μm) – far beyond the 3 microns (0.3μm) of a traditional HEPA filter. Kronos® not only collects but destroys air pollutants. Kronos® AIR 5G® Air Purifiers use about 30,000 volts inside to actively destroy 99.99% of all airborne bacteria, mold, and virus particles.

Kronos® devices operate silently using nanotechnology to remove 100% of pollutants in a 400ft2 room (up to the whole house) and replenishes the room with pure, clean air every 15 minutes. Indoor household air is often four times more polluted than outdoor air, and Kronos air purifiers act like bionic lungs for the home and protect the people in it.

Unlike traditional HEPA systems that collect pollutants on filters which can, over time, grow mold and bacteria, Kronos’ patented technology destroys and eliminates all manner of harmful particles and deposits them on easy-to-clean collecting plates. This reduces the risk of harmful particles in the air and eliminates the need to replace costly HEPA filters every month.

The Kronos® AIR 5G® Air Purifier destroys and eliminates dust, allergens, bacteria, and even viruses. The AIR 5G® has been third party lab tested and confirmed to kill 99.87% of influenza virus in one hour.

The patented system’s five step process starts with a pre-filter screen that filters and collects hair, pet dander, etc. The air is then pulled through emitter wires which create a 30,000-volt electro field that zaps dangerous particulates. In the ionic field, charged particles are destroyed, killing bacteria and pathogens. The particles are then captured on collecting plates, removing dangerous toxins from circulation. The collecting plate is easily cleaned and reused without buying new filters. The catalytic layer is the final step in the purification process, removing odors and keeping the air fresh and pure. The AIR 5G® has Smart Control Auto Mode, which measures and displays the air quality in the room and self-adjusts fan speed based on how dirty the air is in the room. There’s also an AIR 5G® Smart App that displays the real time Air Quality Index and acts as a remote control.

The Kronos® AIR 5G® Air Purifier is offered in three models:

• Kronos® AIR 5G® X3 air purifier combines powerful patented TPA® technology with a compact form factor up to six times smaller than other air purifiers, with washable and reusable filters.
• Kronos® AIR 5G® X5 thoroughly wipes out dust, smoke, dander, bacteria, pollen, viruses, odors, germs, and more from the air, delivering the healthiest breathable air possible. It was developed for some of the world’s most polluted areas and is now available for use in the home. It runs completely silently, passing through five stages of purification to guarantee the cleanest possible air in homes or offices.
• Kronos® AIR 5G® X8 delivers maximum power, more than doubling the capacity and efficiency of the Kronos X5, with CADR speeds of up to 470 CFM – enough to clean a 1,000ft2 room in just 20 minutes.

Kronos also offers the Kronos Car Air Purifier, the most advanced car air purifier with Kronos’ patented TPA® technology, and FitAir, the best personal air purifying solution that brings clean air anywhere by cleaning within 25ft2 of personal space at an airflow rate of 3x per hour.

Market Overview

The global air purifier market was valued at $10.38 billion in 2020 and is expected to reach $21.15 billion by 2027, achieving a CAGR of 10.7% over the forecast period, according to Brandessence Market Research. The market is primarily driven by the increasing concerns about both outdoor and indoor air pollution, coupled with the associated health problems.

Air pollution is one of the most prevalent concerns, due to worsening environmental condition. According to Health Effect Institute, it accounts for 4.9 million to 8.8 million deaths worldwide each year. Furthermore, as most of our time is spent is indoors, indoor air pollution remains a serious concern to individuals, as well as regulatory agencies. Particles like PM 2.5 can enter indoors through a wide range of sources including car engines, fireplaces, and coal- or natural gas and the infiltration of ambient particulates in urban areas. Even in the absence of solid fuels, indoor ventilation can build up PM 2.5 particles to a greater extent than in outdoor environments. Growing demand for portable air purification filters and systems in urban areas, increased advancements to catch key particulates like coronavirus, and increased regulatory measures to ensure safe environments for professionals in the industrial sector remain leading drivers of growth in the air purifier market.

Poor indoor air quality can cause fatigue, headache, and irritation of the eyes, throat, lungs, and nose, which can have a negative impact on worker productivity. Some air contaminants can cause asthma and other respiratory diseases.

Air purifier adoption is increasing rapidly in the U.S. to minimize health issues caused by poor air quality. Strict air quality standards, guidelines, and regulations in the U.S. are expected to have a positive impact on the market. For instance, the New Jersey Indoor Air Quality standard, NJAC 12:100-13 (2007), sets guidelines and standards related to indoor air quality during working hours in public employee-occupied buildings.

Key manufacturers are focusing on acquisitions and mergers to expand their geographical reach and strengthen their position in the market.

Management Team

Michael Rubinov, President and Head of Business Development

A seasoned hi-tech executive with 25 years of global business experience, Mr. Rubinov has served in various positions in sales, marketing, channel development and partner management. He has worked for large and global organizations such as Intel, NICE Systems, and Boeing (Defense and Security), as well as for start-up companies like Dialogic and Remunera International SA. He was appointed President and Head of Business Development of Kronos Advanced Technologies Inc. in February 2020. Mr. Rubinov holds an MBA, an MS Computer Sciences, and a BS Electrical Engineering.

Joseph L. Florence, Chief Operational Officer & CTO

A dynamic skilled leader in all aspects of business formation, evaluation, and execution, Mr. Florence brings a unique combination of Fortune 100 company experience with a lifetime of entrepreneurial experience to the Kronos team. He is a gifted visionary, possessing the unique ability to see future opportunities and make timely strategic adjustments and is naturally gifted at seeing unrecognized risk and overlooked opportunities. Mr. Florence has a proven track record of transforming companies to better align people, processes, and technologies to meet strategic goals and business metrics resulting in increased market share and profitability.

Kronos Advanced Technologies Inc. (OTC: KNOS), closed Thursday's trading session at $0.0149, off by 12.3529%, on 9,806 volume. The average volume for the last 3 months is 9,806 and the stock's 52-week low/high is $0.01/$0.0785.

Recent News

• Kronos Advanced Technologies Inc. (OTC: KNOS) - InvestorNewsBreaks - Kronos Advanced Technologies Inc. (KNOS) Continues Transformation to Globally Dominant Consumer Product Design, Manufacturing Company
• Kronos Advanced Technologies Inc. (KNOS) Committed to Providing Best Protection, Best Technology Amid Lingering Pandemic
• Kronos Advanced Technologies Inc. (KNOS) Closes on Milestone Acquisition, Moves Forward with American-Made Manufacturing Plan